About the Event
MAIA Biotechnology (NYSE: MAIA) and Regeneron are evaluating THIO in sequential administration with Libtayo in a Phase 2 clinical trial for advanced Non-Small Cell Lung Cancer. THIO is a telomere targeting agent that attacks cancer in a whole new way. It is picked up by telomerase and undermines the telomeric structure, killing the 70-90% of the cancer cells in just 24-72 hours. It also creates an immune response so effective that if THIO is followed by a checkpoint inhibitor like Libtayo, it leads to complete response and no recurrence in preclinical trials. It also enables the immune cells to recognize the cancer cells and kill them without any additional therapy. After successfully completing safety studies, the companies are now enrolling and dosing patients in Phase 2 trials to demonstrate the effectiveness of sequential therapy.
THIO is a platform technology and MAIA currently has 2 programs in progress targeting multiple cancer types in addition to Non-Small Cell Lung Cancer, including Small Cell Lung Cancer, Colorectal, HCC, and other solid tumor cancer indications. They have received 2 orphan drug designations from the FDA. And there are several important milestones approaching including preliminary efficacy data and the initiation of a new basket umbrella study.
Join our webinar with Vlad Vitoc, CEO of MAIA as he shares the latest news on the Phase 2 trial and the company’s other programs.